Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Health Catalyst (HCAT) EBITDA (2018 - 2025)

Health Catalyst's EBITDA history spans 8 years, with the latest figure at -$82.1 million for Q4 2025.

  • For Q4 2025, EBITDA fell 478.03% year-over-year to -$82.1 million; the TTM value through Dec 2025 reached -$145.9 million, down 155.86%, while the annual FY2025 figure was -$145.9 million, 155.86% down from the prior year.
  • EBITDA reached -$82.1 million in Q4 2025 per HCAT's latest filing, down from -$13.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$10.6 million in Q3 2024 to a low of -$82.1 million in Q4 2025.
  • Average EBITDA over 5 years is -$29.2 million, with a median of -$30.1 million recorded in 2022.
  • Peak YoY movement for EBITDA: surged 59.56% in 2024, then plummeted 478.03% in 2025.
  • A 5-year view of EBITDA shows it stood at -$42.8 million in 2021, then grew by 21.56% to -$33.5 million in 2022, then increased by 11.51% to -$29.7 million in 2023, then soared by 52.16% to -$14.2 million in 2024, then tumbled by 478.03% to -$82.1 million in 2025.
  • Per Business Quant, the three most recent readings for HCAT's EBITDA are -$82.1 million (Q4 2025), -$13.7 million (Q3 2025), and -$33.5 million (Q2 2025).